期刊文献+

阿司匹林干预野百合碱诱导的大鼠肺动脉高压的研究 被引量:3

The effects of aspirin on monocrotaline-induced pulmonary arterial hypertension in rats
下载PDF
导出
摘要 目的 探讨阿司匹林对野百合碱(MCT)诱导的大鼠肺动脉高压的作用.方法 雄性Sprague Dawley(SD)大鼠120只,随机分为6组,每组20只,分别为:正常对照组(Ctrl组)、肺动脉高压组(PAH组)和阿司匹林不同剂最治疗组(ASA 0.5组,ASA 1组,ASA 2组,ASA 4组).PAH组、阿司匹林各剂量治疗组于第0天一次性腹腔注射MCT 50 mg/kg.从第1天开始,阿司匹林各剂量治疗组分别给予阿司匹林0.5、1.0、2.0 mg·kg-1和4.0mg·kg-1·d-1灌胃,共30 d.第31天,对各组大鼠进行以下检测:(1)统计大鼠的体质量和生存率 (2)右心导管法测定肺动脉收缩压(sPAP) (3)心脏大体标本测定右心室肥厚指数(RVHI) (4)肺组织染色切片,运用IPP 6.0图像分析软件测定肺小动脉增厚指数(PATI).结果 与PAH组比较,ASA 2组和ASA 4组体质量增加[(464.6±62.6)g和(473.2±77.2)g比(424.9±68.5)g,均为P〈0.05] ASA各治疗组合计生存率较PAH组明显提高(83.75%比60.00%,P〈0.05) 与PAH组比较,ASA各治疗组sPAP明显下降(均为P〈0.05),RVHI显著降低(均为P〈0.05) 除ASA 0.5组以外,其他阿司匹林治疗组的PATI较PAH组明显降低(均为P〈0.05).结论 阿司匹林1、2 mg·kg-1·d-1和4 mg·kg-1·d-1能有效降低野百合碱诱导的肺动脉高压大鼠的肺动脉压力,减轻右心室肥厚和肺小动脉增生. Objective To explore the effects of aspirin on moncrotaline-induced pulmonary arterial hypertension in rats. Methods 120 Sprague-Dawley rats were randomly divided into six groups with each for 20: normal control group (Ctrl group) , untreated pulmonary arterial hypertension group (PAH group) and various aspirin-dosage treated pulmonary arterial hypertension group ( ASA 0. 5, 1.0, 2. 0 and 4. 0 mg ~ kg - 1 . d - 1 by intragastrically after monoerotaline injection from day 1 to day 30 ). The pulmonary arterial hypertension was induced by intraperitoneal injection of 50 mg/kg monocrotaline on day 0. On day 31, results were measured as following: (1)Survival rates and weights were measured; (2) Right heart catheter was performed to measure systolic Pulmonary Arterial Pressure (sPAP) ; (3)Heart specimens were separated and weighed to determine the Right Ventricular Hypertrophy Index (RVHI) ; (4)With pulmonary arterioles staining, Pulmonary Arterioles Thickness Index (PATI) were evaluated by IPP 6. 0 image analysis software. Results In comparison with PAH group, weights in ASA 2 group and ASA 4 group were increased ( P 〈 0. 05 respectively). Survival rates were significantly increased in overall ASA treatment group compared with PAH group ( P 〈 0.05 respectively ). sPAPs and RVHIs in various ASA treatment group were significantly decreased than that in PAH group ( P 〈 0. 05 respectively) ; PATIs in ASA treatment group, except ASA 0. 5 group, were significantly decreased than that in PAH group (P 〈 0. 05 respectively). Conclusions Aspirin ( ASA 1, ASA 2 and ASA 4) could reduce pulmonary arterial pressure,attenuates right ventricular hypertrophy and pulmonary arterioles proliferation in monocrotaline-induced pulmonary arterial hypertension model.
出处 《中国心血管杂志》 2010年第5期375-379,共5页 Chinese Journal of Cardiovascular Medicine
基金 上海市卫生局课题项目资助(2007103)
关键词 高血压 肺性 阿司匹林 野百合碱 Pulmonary arterial hypertension Aspirin Monocrotaline
  • 相关文献

参考文献20

  • 1Bubin LJ,Badesch DB.Evaluation and management of the patient with pulmonary arterial hypertension.Ann Intern Med,2005,143:282-292. 被引量:1
  • 2Tuder RM,Marecki JC,Richter A,et al.Pathology of pulmonary hypertension.Clin Chest Med,2007,28:23-42. 被引量:1
  • 3MacLean MR,Herve P,Eddahibi S,et al.5-hydroxytryptamine and the pulmonary circulation:receptors,transporters and relevance to pulmonary arterial hypertension.Br J Pharmacol,2000,131:161-168. 被引量:1
  • 4Wagenvoort CA,Mulder PG.Thrombotic lesions in primary plexogenic arteriopathy.Similar pathogenesis or complication? Chest,1993,103:844-849. 被引量:1
  • 5Fuster V,Steele PM,Edwards WD,et al.Primary pulmonary hypertension:natural history and the importance of thrombosis.Circulation,1984,70:580-587. 被引量:1
  • 6Kawut SM,Hom EM,Berekashvili KK,et a.L New predictors of outcome in idiopathic pulmonary arterial hypertension.Am J Cardiol,2005,95:199-203. 被引量:1
  • 7Bedesch DB,Abman SH,Simonneau G,et al.Medical therapy for pulmonary arterial hypertension:updated ACCP evidence-based clinical practice guidelines.Chest,2007,131:1917-1928. 被引量:1
  • 8Newman JH,Fanburg BL,Archer SL,et al.Pulmonary arterial hypertension:future directions:report of a National Heart,Lung and Blood Institute/Office of Rare Diseases workshop.Circulation,2004,109:2947-2952. 被引量:1
  • 9McLaughlin W,Archer SL,Badesch DB,et al.ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians;American Thoracic Society,Inc.;and the Pulmonary Hypertension Association.J Am Coll Cardiol,2009,53:1573-1619. 被引量:1
  • 10Nishimura T,Faul JL,Berry GJ,et al.Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rata.Am J Respir Crit Care Med,2002,166:1403-1408. 被引量:1

同被引文献65

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部